Werewolf Therapeutics, Inc. (HOWL) Stock Price & Analysis

Werewolf Therapeutics, Inc. (HOWL) fell 1.94% to USD 0.37 as of June 10, 2026 at 00:53 UTC, according to Nexqual real-time market data.

HOWL last closed at USD 0.38; the session ranged USD 0.36–0.39 on volume of 1,125,009 shares. Market capitalization is $18.20M, with a 52-week range of USD 0.36–2.38 (NMS). Source: Nexqual, June 10, 2026 at 00:53 UTC.

Key Statistics (as of June 10, 2026 at 00:53 UTC)

Technical Analysis (HOWL)

Nexqual's technical model rates HOWL "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:53 UTC.

Analyst Ratings (HOWL)

Wall Street analysts rate HOWL "None" based on 1 analysts, with a mean price target of USD 4 (range USD 4–4), per Nexqual as of June 10, 2026 at 00:53 UTC.

Earnings (HOWL)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:53 UTC.

Financials & Fundamentals (HOWL)

Source: Nexqual, June 10, 2026 at 00:53 UTC.

Financial Health Score (HOWL)

Nexqual rates Werewolf Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:53 UTC.

Ownership (HOWL)

Source: Nexqual, June 10, 2026 at 00:53 UTC.

Leadership (HOWL)

Werewolf Therapeutics, Inc. is led by Daniel J. Hicklin (age 61), Founder, CEO, President, Secretary & Director, per Nexqual as of June 10, 2026 at 00:53 UTC.

Major Backers & Investors (HOWL)

Notable institutional backers of Werewolf Therapeutics, Inc. include RA Capital Management, L.P., MPM Bioimpact LLC, Lynx1 Capital Management Lp, according to Nexqual as of June 10, 2026 at 00:53 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:53 UTC.

From Werewolf Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)

Key Strengths & Strategy (as disclosed to the SEC)

• We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies.
• We have provided initial preclinical data for our proprietary INDUCER™ T cell engager molecules demonstrating that our PREDATOR masking technology silenced peripheral activity and prevented cytokine release.
• Once our molecules are cleaved within the tumor, the cytokine is released for either intratumoral target binding or rapid systemic clearance. 7 Table of Contents • Conditional Activation : Upon reaching the TME, INDUKINE molecules are activated via cleavage of our proprietary linkers by tumor-specific proteases which results in release of the cytokines in the tumor.
• Key features of WTX-124 include preservation of full IL-2 potency and function as observed in preclinical studies, high affinity blockade of IL2—IL2R interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and conditional protease activation within the TME due to our proprietary linker.

Partnerships

• In June 2024, we executed a transfer agreement, or the Transfer Agreement, to assign our rights in a development agreement with a contract manufacturer of our interferon alpha INDUKINE molecule JZP898 to Jazz.
• We are currently seeking a strategic partnership for the further development of WTX-124.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:53 UTC. This page is informational and not investment advice.